TITLE:
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer

CONDITION:
Gastroesophageal Adenocarcinoma

INTERVENTION:
OSI-7904L

SUMMARY:

      Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety
      of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit
      after two cycles may be switched to a commonly used combination regimen.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

        Documented locally advanced or metastatic adenocarcinoma of the stomach or
        gastroesophageal junction No prior chemotherapy for locally advanced or metastatic disease
        Adequate baseline bone marrow, hepatic and renal function Age >= 18 years At least one
        target lesion

        Exclusion Criteria:

        Active or uncontrolled infections or other serious illnesses or other medical conditions
        (eg, hepatitis, HIV, chronic alcohol abuse) Symptomatic brain metastases which are not
        stable
      
